Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | NEPH Nephros, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $4.23 -1.7% | $15.37 -0.2% |
| StockIQ Score | 57C Moderate Risk: Medium | 35F Weak Risk: High |
| Technical | 48D+ | 13F |
| Fundamental | 63C+ | 35F |
| Growth | 74B | 50C- |
| Fair Value | 45D+ | 38F |
| News | 62C+ | 50C- |
| Quality | 58C | 50C- |
| Risk | 48D+ | 40D |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
NEPH outperforms AAPG in every reported metric. Its investor score (57 vs 35), technical (48 vs 13), fundamental (63 vs 35), growth (74 vs 50) and valuation (45 vs 38) are all higher, with the biggest gap in growth. Overall, NEPH shows a stronger profile across all categories.
